Amlodipine formulations

A method of treating hypertension in a subject comprising administering to the subject an oral liquid formulation, wherein the oral liquid formulation comprises:

• (i) amlodipine benzoate in an amount corresponding to 1.0 mg/ml amlodipine freebase;
• (ii) 3 mM of a citrate buffer;
• (iii) 0.2 mg/ml to about 10 mg/ml of sodium benzoate;
• (iv) 0.5 mg/ml of silicon dioxide;
• (v) 7.5 mg/ml of hydroxypropyl methylcellulose;
• (vi) 0.15 mg/ml simethicone;
• (vii) 1.0 mg/ml of polysorbate 80;
• and
• (viii) water;
• wherein the pH of the formulation is between 4 and 6, and wherein the formulation is stable at 5±5° C. for at least 12 months;
• and wherein the stable oral liquid formulation has 95% w/w or greater of the initial amlodipine amount and 5% w/w or less total impurities or related substances at the end of the given storage period.